Mozzanica N, Cattaneo A, Boneschi V, Brambilla L, Melotti E, Finzi A F
Second Department of Dermatology, University of Milan, Italy.
Arch Dermatol Res. 1990;282(5):311-7. doi: 10.1007/BF00375725.
We investigated the peritumoral and intratumoral immune infiltrate in 6 basal cell carcinomas (BCCs) treated with recombinant alpha 2b-interferon. Each BCC was injected intralesionally three times a week for 3 weeks with 1.5 x 10(6) IU of interferon per injection (total dose 13.5 x 10(6) IU). The immunohistological study was done before the start of interferon therapy and 15 days afterwards, using a series of monoclonal antibodies and an immunocytochemical technique. Before therapy the infiltrate consisted mainly of CD3+ (T) cells, with prevalence of CD4+ (helper/inducer) T cells. The percentage of T cells expressing interleukin-2 receptor (CD25+ cells) was higher in the tumor nests than in the peritumoral infiltrate (20% and 11% respectively). CD1+ (Langerhans) cells and CD14b+ cells (monocytes/macrophages) were present in the peritumoral infiltrate in all cases (9% +/- 5% and 14% +/- 7% respectively). Very few CD56+ (natural killer), CD15+ (granulocytes) and CD20+ (B) cells were observed in the peritumoral infiltrate and none at all in tumor nests. After 15 days of interferon therapy, we observed an increase in peritumoral and intratumoral CD4+ cells. There was a decrease in the number of CD25+ cells and of CD1+ cells in the peritumoral infiltrate. The number of intratumoral CD25+ increased. No variations were seen in CD14b, CD15, CD20, and CD56 positive cells. Eight weeks after completion of therapy, two BCCs were cleared and the remaining four showed clinical and histological improvement. These results may indicate a direct effect of interferon against BCC; in addition the immunohistological findings suggest that intralesional interferon enhances T cell mediated immune response, especially in tumor nests.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了6例接受重组α2b干扰素治疗的基底细胞癌（BCC）的瘤周和瘤内免疫浸润情况。每例BCC每周进行3次瘤内注射，共3周，每次注射1.5×10⁶国际单位（IU）的干扰素（总剂量13.5×10⁶IU）。在干扰素治疗开始前及治疗15天后，采用一系列单克隆抗体和免疫细胞化学技术进行免疫组织学研究。治疗前浸润细胞主要为CD3⁺（T）细胞，以CD4⁺（辅助/诱导）T细胞为主。肿瘤巢中表达白细胞介素-2受体的T细胞（CD25⁺细胞）百分比高于瘤周浸润（分别为20%和11%）。所有病例的瘤周浸润中均存在CD1⁺（朗格汉斯）细胞和CD14b⁺细胞（单核细胞/巨噬细胞）（分别为9%±5%和14%±7%）。在瘤周浸润中观察到极少量的CD56⁺（自然杀伤）、CD15⁺（粒细胞）和CD20⁺（B）细胞，肿瘤巢中则完全没有。干扰素治疗15天后，我们观察到瘤周和瘤内CD4⁺细胞增加。瘤周浸润中CD25⁺细胞和CD1⁺细胞数量减少。瘤内CD25⁺细胞数量增加。CD14b、CD15、CD20和CD56阳性细胞未见变化。治疗完成8周后，2例BCC清除，其余4例显示临床和组织学改善。这些结果可能表明干扰素对BCC有直接作用；此外，免疫组织学结果提示瘤内干扰素增强了T细胞介导的免疫反应，尤其是在肿瘤巢中。（摘要截短于250字）
